Efficacy of recombinant glycoprotein D subunit vaccines on the development of primary, recurrent, and latent genital infections with herpes simplex virus type 2 in guinea pigs.
Vaccination of guinea pigs with recombinant glycoprotein D (subunit vaccine) from either herpes simplex virus type 1 or type 2 (HSV-1, HSV-2), before intravaginal inoculation with HSV-2, markedly altered viral replication in the vaginal tract and reduced, or completely prevented, the development and spread of external genital lesions. Vaccination with glycoprotein D from HSV-2 prevented the establishment of latent HSV-2 infections in dorsal root ganglia and reduced the frequency of recurrent episodes. For all parameters of efficacy that we tested, vaccination with glycoprotein D from HSV-2 was more effective than was vaccination with protein derived from HSV-1. Vaccination after primary infection had no effect on the frequency or duration of recurrent HSV-2 infections.
Berman
P W
PW
Department of Molecular Biology, Genentech, Incorporated, South San Francisco, California 94080.
Vogt
P E
PE
Gregory
T
T
Lasky
L A
LA
Kern
E R
ER
D000818:Animals; D000941:Antigens; D005260:Female; D005727:Ganglia, Spinal / Q000382:microbiology; D006168:Guinea Pigs; D006558:Herpes Genitalis / Q000382:microbiology / Q000517:prevention & control*; D012008:Recurrence; D018139:Simplexvirus / Q000276:immunology / Q000302:isolation & purification; D014611:Vaccination; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins / Q000276:immunology*; D014765:Viral Vaccines
D000941:Antigens; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C039447:glycoprotein D, Human herpesvirus 1; C040570:glycoprotein D-herpes simplex virus type 2